Anna is an Associate Director in Osborne Clarke's Intellectual Property team. Anna advises clients on all aspects of intellectual property law including clearance, protection and litigation across all IP rights.
Anna has experience of high profile patent litigation in the life sciences and tech, media and communications sectors. She has particular expertise in managing parallel actions across Europe. Anna's patent cases have involved core biotechnologies, such as therapeutic antibodies, generic pharmaceuticals, telecommunications standards, and innovative mechanical retail products.
Anna's trade mark litigation cases have involved seeking a declaration of non-infringement in respect of well-known marks, a cross-border passing off claim relating to the VFX industry, and enforcing trade mark rights in the context of a comparative advertising dispute.
Anna regularly speaks on IP issues including at the Commercial Dispute Resolution Life Sciences Litigation Symposium on "Managing Complex Litigation". She also interviewed Baroness Hale, the then President of the UK Supreme Court for IPSoc, and organised and led a World Intellectual Property Day Event on "Ingenious Women".
Anna co-wrote the UK Copyright chapter in "Getting the Deal Through", and has been published in the Licensing Journal on the UK Supreme Court FRAND licensing dispute, Unwired Planet v Huawei. Anna has also contributed to Leading Internet Case Law magazine on the IP issues relating to Google's AdSense programme, and to CDR Magazine on second medical use patent claims.
Anna is ranked as an IP Stars, Rising Star (2020 and 2019). She is the Chair of IPSoc, the society for junior IP practitioners. Anna holds a Postgraduate Diploma in IP Law and Practice and a Masters' degree with Distinction from Oxford University, as well as a First Class Honours degree from the University of Edinburgh. Anna qualified in 2014 and joined Osborne Clarke in 2016.
Insights
Unwired Planet unpacked: are English courts the de facto global tribunal for SEP licensing disputes?
Is the UK now effectively the forum for determining global FRAND licence terms, and, if so, is that a bad...
Supreme Court Unwired Planet case unpacked: where will implementers turn next in FRAND disputes?
Landmark final appeal ruling means implementers of standards will now face the prospect of the English court setting worldwide licence...
A shot in the arm for generics as UK courts refuse injunction to prevent potential patent infringement
In an unusual decision for life sciences patent disputes, the UK courts refused to restrain a generic drug manufacturer from...
UK Supreme Court gives "skinny label" products (tentative) go ahead – good news for generic pharmaceutical companies and the NHS?
The decision in Warner Lambert v Actavis is good news for generic pharmaceutical companies who will feel emboldened to continue...